NARCOLEPSY TYPE 1 (NT1)
Clinical trials for NARCOLEPSY TYPE 1 (NT1) explained in plain language.
Never miss a new study
Get alerted when new NARCOLEPSY TYPE 1 (NT1) trials appear
Sign up with your email to follow new studies for NARCOLEPSY TYPE 1 (NT1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New narcolepsy drug VX-433 enters first human safety tests
Disease control Recruiting nowThis early-stage study tests a new drug called VX-433 in 118 people with narcolepsy type 1. The main goal is to check if it is safe and how the body processes it. Researchers will also see how VX-433 interacts with other drugs like midazolam and bupropion. This is a first step to…
Matched conditions: NARCOLEPSY TYPE 1 (NT1)
Phase: PHASE1 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New narcolepsy drug TAK-861 put to the test in withdrawal trial
Disease control Recruiting nowThis study tests whether TAK-861 can control symptoms of narcolepsy type 1, a condition causing sudden sleep attacks and muscle weakness. About 88 adults will take TAK-861 for several months, then some will switch to a placebo to see if symptoms return. The goal is to see if the …
Matched conditions: NARCOLEPSY TYPE 1 (NT1)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC